404
Latest news
- February 29th, 2024
From Images to Impact: Radiomics' Solutions to Challenges in Immunotherapy
Up to 30% of patients may experience hyper progression following immunotherapy. Identifying patients who will actually benefit from immunotherapy is intrinsic to achieving optimal outcomes. Radiomics can offer a solution to this problem by analysing the phenotypical changes in lesions and organs that may occur following the initiation of a treatment.
- September 5th, 2023
Pilot project at the Jewish General Hospital aims to accelerate access to new and highly effective treatments for cancer patients
Pilot project at the Jewish General Hospital aims to accelerate access to new and highly effective treatments for cancer patients
- April 7th, 2023
Belgian biotech companies DeuterOncology and Radiomics combine their expertise to improve cancer therapy
DeuterOncology joins forces with Radiomics to develop a clinical tool to predict patient response to treatment.